Categories Earnings, Health Care

Akebia Therapeutics (AKBA) Q4 2019 Earnings Snapshot

— Akebia Therapeutics (NASDAQ: AKBA) reported fourth quarter 2019 loss of $0.79 per share vs. expected loss of $0.47 per share.

— Revenue rose 16% to $69.6 million vs. $93.15 million expected.

Earnings Update by AlphaStreet

— Net product revenue more than quadrupled to $28.9 million from $6.8 million in the fourth quarter of 2018.

— R&D expenses were $80.4 million for the fourth quarter of 2019 compared to $87.1 million for the fourth quarter of 2018.

— Akebia continues to expect to share the data from global Phase 3 studies of its anemia treatment drug Vadadustat in the second quarter of 2020.

— AKBA stock dipped more than 5% in the pre-market trading session.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Adobe Inc. (ADBE) Stock: Should you invest in this recession-proof tech firm?

Adobe, Inc. (NASDAQ: ADBE) has been dominating the design software space for quite some time, all along staying resilient to macroeconomic fluctuations and market headwinds. The company’s cloud-based applications, offered

Brilliant Earth IPO: Here are a few points to note about this jewelry company that goes public next week

Jewelry has always played a significant role in people’s lives. As life begins to go back to normal after the pandemic and people start attending social events, they are looking

Kontrol Technologies CEO Paul Ghezzi: Our focus is on reinvesting for growth

Tell us about BioCloud, how it’s different from any alternate existing products, and your distribution model. BioCloud exists as a part of Kontrol Technologies and is an innovation within our

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top